Biological properties of "naked" metal nanoparticles.

[1]  Chitta Ranjan Patra,et al.  Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells , 2007 .

[2]  R. Kalluri,et al.  Type IV collagen-derived angiogenesis inhibitors. , 2007, Microvascular research.

[3]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[4]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[5]  M. Hall,et al.  Basis for design and development of platinum(IV) anticancer complexes. , 2007, Journal of medicinal chemistry.

[6]  Shuming Nie,et al.  Nanotechnology for targeted cancer therapy , 2007, Expert review of anticancer therapy.

[7]  Michael J Yaszemski,et al.  Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis , 2007, Journal of nanobiotechnology.

[8]  Vincent M Rotello,et al.  Detection and identification of proteins using nanoparticle-fluorescent polymer 'chemical nose' sensors. , 2007, Nature nanotechnology.

[9]  P. Richardson,et al.  Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma , 2007, Expert review of anticancer therapy.

[10]  J. Folkman.  Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[11]  Chitta Ranjan Patra,et al.  Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells , 2007 .

[12]  Bishara S Atiyeh,et al.  Effect of silver on burn wound infection control and healing: review of the literature. , 2007, Burns : journal of the International Society for Burn Injuries.

[13]  K. Podar,et al.  Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies , 2007, Cell cycle.

[14]  G. Tonon,et al.  Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. , 2007, Cancer research.

[15]  Vincent M Rotello,et al.  Functionalized gold nanoparticles for drug delivery. , 2007, Nanomedicine.

[16]  Chao-Liang Wu,et al.  Amelioration of collagen-induced arthritis in rats by nanogold. , 2007, Arthritis and rheumatism.

[17]  S. Petralia,et al.  Photodelivery of nitric oxide from water-soluble platinum nanoparticles. , 2007, Journal of the American Chemical Society.

[18]  Bing Xu,et al.  FePt@CoS(2) yolk-shell nanocrystals as a potent agent to kill HeLa cells. , 2007, Journal of the American Chemical Society.

[19]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[20]  N. Munshi,et al.  Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). , 2006, Blood.

[21]  Kang L. Wang,et al.  Carbon nanotube-DNA nanoarchitectures and electronic functionality. , 2006, Small.

[22]  T. Shanafelt,et al.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Rich,et al.  Improper use of the term "shrapnel". , 2006, The Journal of trauma.

[24]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[25]  S. Silver,et al.  Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds , 2006, Journal of Industrial Microbiology and Biotechnology.

[26]  J. Folkman,et al.  Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. , 2006, Experimental cell research.

[27]  M. Trop.  Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. , 2006, The Journal of trauma.

[28]  J F Hainfeld,et al.  Gold nanoparticles: a new X-ray contrast agent. , 2006, The British journal of radiology.

[29]  R. Compton,et al.  The use of nanoparticles in electroanalysis: a review , 2006, Analytical and bioanalytical chemistry.

[30]  T. Shanafelt,et al.  Update on risk-stratified management for chronic lymphocytic leukemia , 2006, Leukemia & lymphoma.

[31]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[32]  A. Badros,et al.  Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. , 2005, Clinical advances in hematology & oncology : H&O.

[33]  C. Lok,et al.  Insuffisance rénale aiguë après application topique de sulfadiazine argentique , 2005 .

[34]  D. Mukhopadhyay,et al.  Regulatory role of dynamin‐2 in VEGFR‐2/KDR‐mediated endothelial signaling , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  K. Anderson,et al.  Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. , 2005, Cancer research.

[36]  T. Kubota,et al.  TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. , 2005, Oncology reports.

[37]  D. Mukhopadhyay,et al.  Gold Nanoparticles do not Affect the Global Transcriptional Program of Human Umbilical Vein Endothelial Cells: A DNA-Microarray Analysis , 2005 .

[38]  P. Richardson,et al.  FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. , 2005, Cancer research.

[39]  H. Dvorak,et al.  Angiogenesis: update 2005 , 2005, Journal of thrombosis and haemostasis : JTH.

[40]  R. Kalluri,et al.  Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. , 2005, Biochemical and biophysical research communications.

[41]  M. Yacamán,et al.  Interaction of silver nanoparticles with HIV-1 , 2005, Journal of nanobiotechnology.

[42]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Morgan,et al.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.

[44]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Murray,et al.  Reaction of Au55(PPh3)12Cl6 with thiols yields thiolate monolayer protected Au75 clusters , 2005 .

[46]  Ling Wang,et al.  Antiangiogenic Properties of Gold Nanoparticles , 2005, Clinical Cancer Research.

[47]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2005, Future oncology.

[48]  G. Whitesides,et al.  Self-assembled monolayers of thiolates on metals as a form of nanotechnology. , 2005, Chemical reviews.

[49]  M. El-Sayed,et al.  Chemistry and properties of nanocrystals of different shapes. , 2005, Chemical reviews.

[50]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[51]  R. Kalluri,et al.  Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Murray,et al.  Does core size matter in the kinetics of ligand exchanges of monolayer-protected Au clusters? , 2005, Journal of the American Chemical Society.

[53]  J. Hainfeld,et al.  The use of gold nanoparticles to enhance radiotherapy in mice. , 2004, Physics in medicine and biology.

[54]  Y. Sheng,et al.  Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis , 2004, International journal of cancer.

[55]  N. Kay,et al.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia , 2004, Current oncology reports.

[56]  K. Dunn,et al.  The role of Acticoat with nanocrystalline silver in the management of burns. , 2004, Burns : journal of the International Society for Burn Injuries.

[57]  Vincent M Rotello,et al.  Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. , 2004, Bioconjugate chemistry.

[58]  R. Kerbel,et al.  Reanalysis of Cancer Drugs , 2004, Clinical Cancer Research.

[59]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[60]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[61]  Raghu Kalluri,et al.  Cancer without disease , 2004, Nature.

[62]  R. Kerbel.  Antiangiogenic drugs and current strategies for the treatment of lung cancer. , 2004, Seminars in oncology.

[63]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[64]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Koch,et al.  Angiogenesis as a target in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[66]  M. Sastry,et al.  Phase transfer of silver nanoparticles from aqueous to organic solutions using fatty amine molecules. , 2003, Journal of colloid and interface science.

[67]  B. Kim,et al.  Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. , 2003, International journal of oncology.

[68]  Manoj Kumar Gupta,et al.  Mechanism and its regulation of tumor-induced angiogenesis. , 2003, World journal of gastroenterology.

[69]  T. Secomb,et al.  Microangiectasias: Structural regulators of lymphocyte transmigration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Silver,et al.  Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. , 2003, FEMS microbiology reviews.

[71]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[72]  G. Tucker.  Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[73]  H. Dvorak,et al.  Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. , 2003, The American journal of pathology.

[74]  R. Kauppinen,et al.  VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses , 2003, Circulation research.

[75]  J L West,et al.  A whole blood immunoassay using gold nanoshells. , 2003, Analytical chemistry.

[76]  S. Singhal,et al.  Novel Therapies in Multiple Myeloma , 2003, International journal of hematology.

[77]  O. Volpert,et al.  Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. , 2003, Cancer cell.

[78]  E. Manseau,et al.  Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis , 2002, The Journal of experimental medicine.

[79]  F. Wolfe,et al.  Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. , 2002, Rheumatology.

[80]  C. Perrett,et al.  Angiogenesis in epithelian ovarian cancer , 2002, Molecular pathology : MP.

[81]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[82]  A. Albini,et al.  The Angiogenic Switch in Solid Tumors: Clinical Implications , 2002, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

[83]  John L Cleveland,et al.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.

[84]  K. Weinberg,et al.  αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.

[85]  Vincent M Rotello,et al.  Inhibition of chymotrypsin through surface binding using nanoparticle-based receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[86]  D. Mukhopadhyay,et al.  Flt-1-mediated Down-regulation of Endothelial Cell Proliferation through Pertussis Toxin-sensitive G Proteins, βγ Subunits, Small GTPase CDC42, and Partly by Rac-1* , 2002, The Journal of Biological Chemistry.

[87]  M. Entman,et al.  Morphological Characteristics of the Microvasculature in Healing Myocardial Infarcts , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[88]  Kenneth C. Anderson,et al.  Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation* , 2002, The Journal of Biological Chemistry.

[89]  C. Ruhrberg,et al.  Endogenous inhibitors of angiogenesis. , 2001, Journal of cell science.

[90]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[91]  Janice A. Nagy,et al.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.

[92]  S. S. Lee,et al.  Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. , 2001, Clinical and experimental rheumatology.

[93]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[94]  X. Bertagna,et al.  Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. , 2000, The Journal of clinical endocrinology and metabolism.

[95]  J. Cawley,et al.  In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. , 2000, Blood.

[96]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[97]  B. Cheson.  Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy. , 2000, Hematology and Cell Therapy.

[98]  M. Forster,et al.  Molecular modelling study of HIV p17gag (MA) protein shell utilising data from electron microscopy and X-ray crystallography. , 2000, Journal of molecular biology.

[99]  M. Pagano,et al.  Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.

[100]  H. Klasen,et al.  A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. , 2000, Burns : journal of the International Society for Burn Injuries.

[101]  H J Klasen,et al.  Historical review of the use of silver in the treatment of burns. I. Early uses. , 2000, Burns : journal of the International Society for Burn Injuries.

[102]  F. caligaris-Cappio,et al.  Biology of chronic lymphocytic leukemia. , 2000, Reviews in clinical and experimental hematology.

[103]  R. Darouiche.  Anti-infective efficacy of silver-coated medical prostheses. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[105]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[106]  G. Wilding,et al.  Drug development in prostate cancer. , 1999, Seminars in oncology.

[107]  N. Ferrara,et al.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. , 1998, The American journal of pathology.

[108]  T. Yoshida,et al.  Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. , 1998, Cancer research.

[109]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[110]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  E. B. Butler,et al.  The Baylor College of Medicine experience with gold seed implantation. , 1997, Seminars in surgical oncology.

[112]  G M Whitesides,et al.  On-line detection of nonspecific protein adsorption at artificial surfaces. , 1997, Analytical chemistry.

[113]  L. Twiggs,et al.  Vascular endothelial growth factor expression in early stage ovarian carcinoma , 1997, Cancer.

[114]  A. Mantovani,et al.  Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.

[115]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[116]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[117]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[118]  A. König,et al.  Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis , 1997, Leukemia.

[119]  F. Sp,et al.  Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. , 1996 .

[120]  A. Morris,et al.  Overview of the Management of AIDS-Related Kaposi's Sarcoma , 1996, The Annals of pharmacotherapy.

[121]  J. Niloff,et al.  Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[122]  M. Rocchi,et al.  Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. , 1996, Circulation.

[123]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[124]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[125]  D. Finkelstein,et al.  A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma , 1996 .

[126]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[127]  W. Wood,et al.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Paul Mulvaney,et al.  Surface Plasmon Spectroscopy of Nanosized Metal Particles , 1996 .

[129]  E. Calleja,et al.  Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. , 1996, Blood.

[130]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[131]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[132]  H. Dvorak,et al.  Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. , 1995, Cancer research.

[133]  E. Manseau,et al.  Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. , 1995, Cancer research.

[134]  H. Dvorak,et al.  Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. , 1995, Cancer research.

[135]  T. Bourne,et al.  Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. , 1994, Journal of the National Cancer Institute.

[136]  D. Connolly,et al.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.

[137]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[138]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[139]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[140]  H. Dvorak,et al.  Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. , 1993, Cancer research.

[141]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[142]  L. Arthur,et al.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. , 1992, Science.

[143]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[144]  C. Bladin,et al.  Argyria from excessive use of topical silver sulphadiazine , 1992, The Lancet.

[145]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[146]  G. Whitesides,et al.  Molecular self-assembly and nanochemistry: a chemical strategy for the synthesis of nanostructures. , 1991, Science.

[147]  Baker,et al.  Wetting films on chemically modified surfaces: An x-ray study. , 1991, Physical review. B, Condensed matter.

[148]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[149]  R. Conyers,et al.  Determination of silver in blood, urine, and tissues of volunteers and burn patients. , 1991, Clinical chemistry.

[150]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[151]  G. Whitesides,et al.  Self-assembled organic monolayers: model systems for studying adsorption of proteins at surfaces , 1991, Science.

[152]  P. Volberding,et al.  Interferon-α2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma , 1991 .

[153]  D. Felson,et al.  The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. , 1990, Arthritis and rheumatism.

[154]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[155]  P. Sadler,et al.  Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. , 1990, Journal of medicinal chemistry.

[156]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[157]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[158]  I. Haiduc,et al.  Rhodium, iridium, copper and gold antitumor organometallic compounds (review). , 1989, In vivo.

[159]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[160]  P. Sadler,et al.  Interaction of the antitumor Au(I) complex [Au(Ph2P(CH2)2PPh2)2]Cl with human blood plasma, red cells, and lipoproteins: 31P and 1H NMR studies. , 1987, Journal of inorganic biochemistry.

[161]  P. Sadler,et al.  The autoxidation and proton dissociation constants of tertiary diphosphines: relevance to biological activity. , 1987, Journal of inorganic biochemistry.

[162]  R. Moll,et al.  Desmosomal plaque-associated vimentin filaments in human ovarian granulosa cell tumors of various histologic patterns. , 1987, The American journal of pathology.

[163]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[164]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[165]  G. Higby,et al.  Gold in medicine , 1982, Gold bulletin.

[166]  C. E. Carlton,et al.  Combined Interstitial and External Radiotherapy in the Definitive Management of Carcinoma of the Prostate , 1980, Cancer.

[167]  K. Stevens,et al.  Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloids , 1978, Cancer.

[168]  A. Hassan,et al.  Prevention of hepatic metastases by intravenous radioactive gold. , 1978, Cancer research.

[169]  Keettel Wc,et al.  Radioisotopes in treatment of stage Ia ovarian cancer. , 1975 .

[170]  Buchsbaum Hj,et al.  The use of radioisotopes as adjunct therapy of localized ovarian cancer. , 1975 .

[171]  C. C. Wang,et al.  A simple afterloading applicator for intracavitary irradiation of carcinoma of the nasopharynx. , 1975, Radiology.

[172]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[173]  A J Thomson,et al.  The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. , 1967, The Journal of biological chemistry.

[174]  C. Moyer,et al.  Treatment of Large Human Burns With 0.5% Silver Nitrate Solution , 1965 .

[175]  C. Moyer.  Some effects of 0.5 per cent silver nitrate and high humidity upon the illness associated with large burns. , 1965, Journal of the National Medical Association.

[176]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[177]  Moyer Ca.  The treatment of burns. , 1955 .

[178]  H. Wheeler,et al.  Experiences with the use of radioactive colloidal gold in the treatment of cancer. , 1955, Annals of surgery.

[179]  S. W. Root,et al.  Intracavitary colloidal radiogold in the treatment of effusions caused by malignant neoplasms. , 1953, Annals of surgery.

[180]  H. Elkins,et al.  Treatment of carcinoma of the prostate by interstitial radiation with radio-active gold (Au 198): a preliminary report. , 1952, The Journal of urology.

[181]  P. Hahn,et al.  Radioactive Metallic Gold Colloids Coated with Silver and their Distribution in the Lung and its Lymphatics following Intra-Pulmonary Administration: Therapeutic Implications in Primary Lung and Bronchiogenic Tumors , 1951, British Journal of Cancer.

[182]  H. Skipper,et al.  The effect of radioactive colloidal metallic gold in the treatment of “acute” AK‐4 leukemia in mice , 1951, Cancer.

[183]  H. C. Aldrich,et al.  Treatment of Burns , 1936 .

[184]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[185]  N. Raje,et al.  Inhibition of the TGF-beta signaling pathway in tumor cells. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[186]  N. Raje,et al.  Inhibition of the TGF-β Signaling Pathway in Tumor Cells , 2007 .

[187]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[188]  W. Goessler,et al.  Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. , 2006, Journal of Trauma.

[189]  M. Fung,et al.  Systemic argyria associated with ingestion of colloidal silver. , 2005, Dermatology online journal.

[190]  V. Keshamouni,et al.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. , 2005, The Journal of clinical investigation.

[191]  C. Lok,et al.  [Topical silver sulfadiazine-induced acute renal failure]. , 2005, Annales de dermatologie et de venereologie.

[192]  R. Murray,et al.  Reaction of Au(55)(PPh(3))(12)Cl(6) with thiols yields thiolate monolayer protected Au(75) clusters. , 2005, Journal of the American Chemical Society.

[193]  N. Ferrara.  The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.

[194]  G. Wilding,et al.  Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) , 2004, Investigational New Drugs.

[195]  P. Alivisatos.  The use of nanocrystals in biological detection , 2004, Nature Biotechnology.

[196]  D. Astruc,et al.  Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. , 2004, Chemical reviews.

[197]  K. Sugimachi,et al.  The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. , 2002, Surgery.

[198]  E. Manseau,et al.  VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. , 2002, Cold Spring Harbor symposia on quantitative biology.

[199]  Ravi Salgia,et al.  Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. , 2002, The Journal of biological chemistry.

[200]  S. Rafla,et al.  Radioactive gold grain implants in recurrent and locally advanced head-and-neck cancers. , 2002, Brachytherapy.

[201]  S. Negrotto,et al.  [Angiogenesis in cancer]. , 2002, Medicina.

[202]  N. Kay,et al.  Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia , 2000, Leukemia.

[203]  W. Steward.  Marimastat (BB2516): Current status of development , 1999, Cancer Chemotherapy and Pharmacology.

[204]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[205]  P. Carmeliet,et al.  Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. , 1999, Current topics in microbiology and immunology.

[206]  C. Shaw III.  Gold-based therapeutic agents. , 1999, Chemical reviews.

[207]  I. Konishi,et al.  Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[208]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[209]  H. Sakahara,et al.  Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. , 1997, British Journal of Cancer.

[210]  R. Buckley,et al.  Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. , 1996, Anticancer Research.

[211]  C. Zaloudek,et al.  Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. , 1996, The Journal of clinical endocrinology and metabolism.

[212]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[213]  S. Ramakrishnan,et al.  Vascular permeability factor gene expression in normal and neoplastic human ovaries. , 1994, Cancer research.

[214]  H. Dvorak,et al.  Nagy JA, Herzberg KT, Dvorak JM, Dvorak HFPathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53(11): 2631-2643 , 1993 .

[215]  D. Hanahan,et al.  Switch to the angiogenic phenotype during tumorigenesis. , 1991, Princess Takamatsu symposia.

[216]  David T. Felson,et al.  THE COMPARATIVE EFFICACY AND TOXICITY OF SECOND LINE DRUGS IN RHEUMATOID ARTHRITIS , 1990 .

[217]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[218]  S. Mahdihassan.  Cinnabar-gold as the best alchemical drug of longevity, called Makaradhwaja in India. , 1985, The American journal of Chinese medicine.

[219]  S. Mahdihassan.  The tradition of alchemy in India. , 1981, The American journal of Chinese medicine.

[220]  P. Hudgins,et al.  Combined interstitial and external radiotherapy in the definitive management of carcinoma of the prostate. , 1980, Cancer.

[221]  H. Latourette,et al.  The use of radioisotopes as adjunct therapy of localized ovarian cancer. , 1975, Seminars in Oncology.

[222]  E. W. Hahn,et al.  The prevention of Ehrlich ascites tumor using intraperitoneal colloidal 198Au. Dose vs. size of inoculum. , 1975, Radiology.

[223]  W. C. Keettel,et al.  Radioisotopes in treatment of stage Ia ovarian cancer. , 1975, National Cancer Institute monograph.

[224]  J. Folkman.  Tumor angiogensis: role in regulation of tumor growth. , 1974, The ... Symposium. Society for Developmental Biology. Symposium.

[225]  S. Mahdihassan.  Colloidal gold as an alchemical preparation. , 1971, Janus; revue internationale de l'histoire des sciences, de la medecine, de la pharmacie, et de la technique.

[226]  W. Faulk,et al.  An immunocolloid method for the electron microscope. , 1971, Immunochemistry.

[227]  C. Moyer,et al.  TREATMENT OF LARGE HUMAN BURNS WITH 0.5 PER CENT SILVER NITRATE SOLUTION. , 1965, Archives of surgery.